| Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond | 2019/02/13 | English | 757 |
| The role of ligand efficiency metrics in drug discovery | 2014/01/31 | English | 757 |
| Drug development from marine natural products | 2008/12/19 | English | 742 |
| Zebrafish as tools for drug discovery | 2015/09/11 | English | 732 |
| Can we safely target the WNT pathway? | 2014/07/01 | English | 727 |
| Antimicrobial host defence peptides: functions and clinical potential | 2020/02/27 | English | 716 |
| A decade of fragment-based drug design: strategic advances and lessons learned | 2007/02/09 | English | 709 |
| The endocannabinoid system and its therapeutic exploitation | 2004/09/01 | English | 703 |
| The safety and side effects of monoclonal antibodies | 2010/03/22 | English | 702 |
| Therapeutic targeting of microRNAs: current status and future challenges | 2014/07/11 | English | 702 |
| Rapamycin passes the torch: a new generation of mTOR inhibitors | 2011/10/31 | English | 700 |
| Senescent cells: an emerging target for diseases of ageing | 2017/07/21 | English | 699 |
| Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application | 2010/01/01 | English | 697 |
| Noncoding RNA therapeutics — challenges and potential solutions | 2021/06/18 | English | 696 |
| Muscle wasting in disease: molecular mechanisms and promising therapies | 2014/12/31 | English | 694 |
| Lessons from 60 years of pharmaceutical innovation | 2009/12/01 | English | 693 |
| Bispecific antibodies: a mechanistic review of the pipeline | 2019/06/07 | English | 692 |
| Idiosyncratic drug hepatotoxicity | 2005/06/01 | English | 689 |
| Tackling the cancer stem cells — what challenges do they pose? | 2014/07/01 | English | 685 |
| Emerging targets in neuroinflammation-driven chronic pain | 2014/06/20 | English | 683 |
| Non-coding RNAs as drug targets | 2016/07/22 | English | 680 |
| Current development of mTOR inhibitors as anticancer agents | 2006/08/01 | English | 680 |
| Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets | 2011/06/01 | English | 679 |
| Development trends for human monoclonal antibody therapeutics | 2010/09/03 | English | 676 |
| Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders | 2010/12/01 | English | 675 |
| Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors | 2005/05/01 | English | 674 |
| Targeting the unfolded protein response in disease | 2013/08/30 | English | 674 |
| Small molecules, big targets: drug discovery faces the protein–protein interaction challenge | 2016/04/11 | English | 673 |
| Finding function in novel targets: C. elegans as a model organism | 2006/04/21 | English | 671 |
| From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery | 2016/01/22 | English | 670 |